Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
What Should Directors Be Asking? Antitrust in the Boardroom
Podcast
Antitrust
Axinn Represents Modular in $4 Billion Acquisition by Qualcomm
Deals & Cases
Antitrust
Will New DOJ Timing Agreement Deliver Faster Merger Clearances?
Axinn Viewpoints
Antitrust
Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector
Byline Articles
Antitrust
Women Leaders in Life Sciences Law
Speaking Engagement
Litigation & Trials
American Bar Association: Inside Antitrust Enforcement—Former Government Perspectives
Webinar
Antitrust
What's the Skinny on SCOTUS' Skinny Label Decision?
Webinar
Intellectual Property
National Bar Association Corporate Counsel Leadership Summit
Speaking Engagement
Antitrust
FTC Prescribes Lower Out-of-Pocket Insulin Costs in Settlement with Caremark
Axinn Viewpoints
Antitrust
